Fundraising Fox
AmpliPhi Biosciences
NYSE: ARMPGlen Allen, US · Washington corporation
Find your way into AmpliPhi Biosciences
Sign up to see every warm intro you have to AmpliPhi Biosciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the AmpliPhi Biosciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Armata is a pharmaceutical company developing phage-based therapeutics to treat antibiotic-resistant bacterial infections. It focuses on addressing the global challenge of antibiotic resistance.
Founders & leadership
DE
David E. BosherExecutive
KW
Kelley WendtExecutive
PY
Philip YoungPresident and CEO2011–2014Philip Young is an executive with experience in public and private company leadership, corporate development, and fundraising. He serves as CEO and Chairman of AmpliPhi Biosciences, which develops phage-based therapeutics for antibiotic-resistant bacterial infections.
DL
Deborah L. BirxChief Executive Officer, Director
Board
JC
Jeremy Curnock CookBoard director
JP
Julian P. KirkBoard director
LD
Louis DrapeauBoard director
MS
Michael S. PerryBoard director
AS
Anthony SmithymanBoard director
Reported raises · per SEC filings
Form D private placements$31M disclosed across 2 rounds · 2013–2015
▶$13MraisedMar 2015 · 21 investors · BiotechnologyRule 506(b)
▶$13MraisedMar 2015 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Louis DrapeauDirector
- Wendy S. JohnsonExecutive Officer, Director
- Baxter F. Phillips, IIIExecutive Officer
- Jeremy Curnock CookExecutive Officer, Director
- David E. BosherExecutive Officer
- Michael S. PerryDirector
- Anthony SmithymanDirector
- Julian P. KirkDirector
- Offering amount
- $13M
- Amount sold
- $13M
- Sales commissions
- $789.6K
- Placement agents
- Roth Capital Partners, LLC, Griffin Securities, Inc.
- First sale
- Mar 2015
- Incorporated
- Corporation, Washington
- Federal exemptions
- 06b
▶$18MraisedJan 2014 · 26 investors · BiotechnologyRule 506(b)
▶$18MraisedJan 2014 · 26 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kelley WendtExecutive Officer
- Philip YoungExecutive Officer, Director
- Baxter Phillips, IIIExecutive Officer
- Jeremy Curnock CookDirector
- Julian KirkDirector
- Anthony SmithymanDirector
- Louis DrapeauDirector
- Michael PerryDirector
- Offering amount
- $18M
- Amount sold
- $18M
- Sales commissions
- $1.1M
- Placement agents
- Griffin Securities, Inc., Roth Capital Partners, LLC
- First sale
- Dec 2013
- Incorporated
- Corporation, Washington
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does AmpliPhi Biosciences do?
- Armata is a pharmaceutical company developing phage-based therapeutics to treat antibiotic-resistant bacterial infections. It focuses on addressing the global challenge of antibiotic resistance.
- How much funding has AmpliPhi Biosciences raised?
- AmpliPhi Biosciences has disclosed $31M raised across 2 rounds.
- Where is AmpliPhi Biosciences headquartered?
- AmpliPhi Biosciences is headquartered in Glen Allen, US.